Related Experiment Video
Updated: Aug 13, 2026

The 6-hydroxydopamine Rat Model of Parkinson's Disease
Published on: October 27, 2021
Specific D1 and D2 dopamine agonists have synergistic effects in the 6-hydroxydopamine circling model in the rat
1Department of Anatomy, Faculty of Medicine, Laval University, Quebec City, Canada.
Abstract:
The effects of SK&F 38393, RU 24213 and quinpirole alone and the synergistic effects of a combination of both subtypes of dopamine agonist on circling behavior were studied in rats with a unilateral lesion of the nigro-striatal pathway. The ability of SCH 23390 and sulpiride to antagonize the synergistic effects induced by SK&F 38393 and RU 24213 in combination were also studied. Finally, the ability of these specific D1 and D2 dopamine antagonists to block the circling induced by two nonspecific dopamine agonists (apomorphine and amphetamine) was investigated. Some animals responded to only one of the selective dopamine agonists but all responded to apomorphine and to the combination of SK&F 38393 plus Ru 24213 or SK&F 38393 plus quinpirole. A powerful synergistic effect was able to antagonize these synergistic effects. The blocking capacity of SCH 23390 and sulpiride was highly diminished in the apomorphine-induced circling model, compared to the amphetamine-induced circling model where normosensitive dopamine receptors are involved. These data suggest an heterogeneous responsiveness to D1, D2D1 plus D2 and mixed D1/D2 dopamine agonists and a strong synergistic effect of the combination of SK&F 38393 plus RU 24213, or SK&F 38393 plus quinpirole. Denervation also induced some changes in the ability of specific dopamine antagonists to block the behavioral response after the administration of non-specific dopamine agonists.
Related Concept Videos
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Adrenergic Agonists: Direct-Acting Agents
These agents can be classified...
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Drugs Affecting Neurotransmitter Synthesis
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

